Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

B. Gordon, Kenneth; Blauvelt, Andrew; Papp, Kim; G. Langley, Richard; A. Luger, Thomas; Ohtsuki, Mamitaro; Reich, Kristian; A. Amato, David; Ball, Susan; Braun, Daniel; S. Cameron, Gregory; Erickson, J.; J. Konrad, Robert; M. Muram, Talia; J. Nickoloff, Brian; Osuntokun, Olawale; J. Secrest, Roberta; Zhao, Fangyi; Mallbris, Lotus; L. Leonardi, Craig

doi:10.1056/nejmoa1512711

Public

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Published in New England Journal of Medicine • Jun 8, 2016

Authors:

Kenneth B. Gordon

Andrew Blauvelt

Kim Papp

Abstract

BACKGROUND: Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo and etanercept in the treatment of moderate-to-severe psoriasis. We report the 60-week data from the UNCOVER-2 and UNCOVER...

Subject

Ixekizumab

Medicine

Psoriasis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!